Reviewer’s report

Title: Clinical Experience with Tigecycline in the Treatment of Hospital-Acquired Pneumonia Caused by Multidrug Resistant Acinetobacter baumannii

Version: 1 Date: 11 Dec 2018

Reviewer: Stefanie Krick

Reviewer’s report:

In the manuscript of Zhou et al., the authors conducted a retrospective study to share their clinical experience using Tigecycline for the treatment of hospital-acquired pneumonia caused by MDR Acinetobacter baumannii. They analyzed data of a total of 77 patient from one hospital, who were treated with tigecycline alone or in combination with another antibiotic and did a multivariate analysis. They found that a shorter duration of tigecycline was associated with increased treatment failure and that an increased 30-day mortality. The authors' conclusion was that tigecycline is a potential antibiotic choice for HAP caused by MDRAB, but a longer treatment duration might be needed. Overall, this is an interesting manuscript and important to share with the scientific community, but there are currently major concerns that should be addressed.

Major concerns:

1. The whole manuscript needs to be edited for the English language due to multiple spelling and grammatical mistakes (“clinical eexperince” in the title, abstract double mentioning "treated with tigecycline line 30/31, lines 49, 62, 68, 140 etc.).

2. Procalcitonin is mentioned in the manuscript line 131, but it is not defined what the criteria directly are, same for the white blood cell count….the improvement of laboratory tests should be better defined.

3. Line 141/142, this method should have references.

4. Line 175…please rephrase "patients involving monoMDRAB.

5. Discussion lines 243-249 is written very confusing, please clarify.

6. Line 253: the authors did not find any difference between monotherapy and combination therapy - this is expected since sample size is too small to detect.

7. It is problematic to state the efficacy of tigecycline, since most patients received a combination therapy…therefore, title is very speculative and should rather state that antibiotic therapies including tigecycline….this should be addressed throughout the manuscript.
8. The change of albumin is not addressed in the results but only in the discussion: is this relevant? It can be most likely omitted.

9. I recommend to include important references: 1. Wu et al., Biomed Res Int. 2016, Xu et al., Chemotherapy 2016.

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.

No

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

Yes

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

No

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Not suitable for publication unless extensively edited

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal